Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacoga Lfa (activated) in hemophilia A or B with inhibitors: efficacy, safety and pharmacokinetics - Mahlangu, J; Levy, H; Khacchatryan, H (Res Pract Thromb Haemost, 2019)
(S1):